Rick Ikesaka, University of Ottawa

Research

Anticoagulation Cancer Central Venous Catheter Randomized Trial Venous Thromboembolism

Latest papers

Pilot trials in thrombosis: Purpose and pitfalls
Research and Practice in Thrombosis and Haemostasis · 2018 · first author
Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis
Thrombosis Research · 2014 · first author

All 2 publications

Latest funding

PREVENT GU: Prevention of thromboembolism with rivaroxaban in GU cancer patients receiving chemotherapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
CIHR · 2022 · Co-investigator
$424,575
Primary thromboprophylaxis with rivaroxaban in patients with malignancy and central venous catheters: TRIM-Line.
CIHR · 2020 · Principal investigator
$1,383,745

All 2 grants and awards

2 publications.

01

Pilot trials in thrombosis: Purpose and pitfalls

Ikesaka R, Langlois N, Carrier M, Kearon C, Le Gal G

Research and Practice in Thrombosis and Haemostasis20184 citationsFirst authorOpen Access

DOI: 10.1002/rth2.12117 PMID: W2808642541

02

Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis

Ikesaka R, Delluc A, Le Gal G, Carrier M

Thrombosis Research201473 citationsFirst author

DOI: 10.1016/j.thromres.2014.01.021

PREVENT GU: Prevention of thromboembolism with rivaroxaban in GU cancer patients receiving chemotherapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial

Co-investigatorCIHR2022Project Grant

Principal investigators: Lavallée, Luke T; Bossé, Dominick; Breau, Rodney H; Carrier, Marc

Keywords: Anticoagulants; Bladder Cancer; Bleeding; Chemotherapy; Genitourinary Malignancy; Thromboprophylaxis

$424,575

Primary thromboprophylaxis with rivaroxaban in patients with malignancy and central venous catheters: TRIM-Line.

Principal investigatorCIHR2020Project Grant

Principal investigators: Carrier, Marc; Ikesaka, Rick T

Keywords: Anticoagulation; Cancer; Central Venous Catheter; Randomized Trial; Venous Thromboembolism

$1,383,745

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Medicine
Department of Medicine

Co-authors at University of Ottawa, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.

Marc Carrier

Department of Medicine

2 shared papers, latest 2018

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2020

Subject: Prospective PhD student: Anticoagulation Dear Professor Ikesaka, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Pilot trials in thrombosis: Purpose and pitfalls" (2018), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Primary thromboprophylaxis with rivaroxaban in patients with malignancy and central venous catheters: TRIM-Line." (2020), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]